

RECEIVED  
CENTRAL FAX CENTER

0001/014

OCT 29 2004

**SCHERING-PLOUGH CORPORATION**  
 LAW DEPARTMENT  
 2000 GALLOPING HILL ROAD  
 K-6-1, MAIL STOP 1990  
 KENILWORTH, NEW JERSEY 07033  
 (908) 298-4000

**FACSIMILE TRANSMITTAL SHEET**

TO: Examiner: R. Mondesi  
 USPTO

FAX NUMBER:  
 (703) 872-9307

FROM: Palaiyur S. Kalyanaraman

PHONE NUMBER:  
 (908) 298-5068

TOTAL NO. OF PAGES INCLUDING COVER  
 14

DATE  
 October 29, 2004

**CONFIDENTIALITY NOTE:** This sheet and/or the document(s) accompanying it contain information belonging to Schering-Plough Corporation and/or its affiliates which is confidential and/or legally privileged. The information is intended only for the use of the individual or entity named above. If you have received this fax in error, please immediately notify us by telephone. If there is a problem with this transmission please call Ashly Armstrong at (908) 298-4025.

NOTES/COMMENTS:

**PLEASE HAND DELIVER**In re Application of: Z. Zhu *et al.*

For Patent entitled: "Diaryl Peptides as NS3-Serine Protease Inhibitors of Hepatitis C Virus"

Group Art Unit: 1653

Filed: 12/10/2001

Attorney Docket No.: IN01174

Serial No.: 10/013,071

Dear Examiner Mondesi,

Transmitted herewith are:

- Fax Cover Sheet – 1pg.
- Certificate of Transmission under 37 CFR 1.8 – 1pg.
- Response Transmittal (PTO/SB/21) – 1pg.
- Amendment (After Final) – 11 pages

  
 Palaiyur S. Kalyanaraman  
 Registered Representative  
 Registration No. 34,634

PHONE: (908) 298-5068

FAX: (908) 298-5388

Attorney Docket No.: IN01174  
Application No.: 10/013,071  
Filing Date: 12/10/2001  
First Named Inventor: Z. Zhu

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

RECEIVED  
CENTRAL FAX CENTER

OCT 29 2004

PTOM58/97 (03-03)

Approved for use through 07/31/2008, OMB 0651-0221  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

## Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office (Fax No. 703-872-9307)

on 10/29/2004  
Date

  
Signature

Palaiyur S. Kalyanaraman, Reg. No. 34,634

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Document(s) being transmitted:

- Fax Cover Sheet - 1pg.
- Certificate of Transmission - 1pg.
- Response Transmittal - 1pg.
- Amendment (After Final) - 11pgs.

This collection of information is required by 37 CFR 1.6. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.8 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/21 (02-04)

Approved for use through 07/31/2006, CMS 0651-0051  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/013,071
Filing Date	12/10/2001
First Named Inventor	Z. Zhu
Art Unit	1653
Examiner Name	R. Mondesi
Total Number of Pages in This Submission	14
Attorney Docket Number	IN01174

**ENCLOSURES (Check all that apply)**

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Group
<input type="checkbox"/> <input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> <input checked="" type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> <input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	<input type="checkbox"/> Fax Cover Sheet - 1pg.
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> Certificate of Transmission - 1pg.
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm or Individual name: Palaiyur S. Kalyanaraman, Reg. No. 34,634

Signature:

Date: 10/29/2004

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name:

Signature:

Date:

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

OCT 29 2004

PATENT CASE: IN01174-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	x
Z. Zhu et al	:
Serial No.: 10/013,071	:
Filed: 12/10/2001	:
For: "Diaryl Peptides as NS3-Serine Protease Inhibitors of Hepatitis C Virus"	:

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

AMENDMENT AFTER FINAL REJECTION PER 37 C.F.R § 1.116

Sir:

This communication is in response to the Office Action that the Examiner issued on September 22, 2004, in the above-identified patent application. Claims 1-18 and 21-23 are pending in the case; claims 1-18 and 21-23 stand finally rejected. Applicants respectfully request entry of the following Amendment after Final Rejection. This communication is being faxed to the Examiner's attention at 703-872-9307.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 10 of this paper.